Mainland China
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021
SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...
2021-06-07 10:11
7285
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021
* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...
2021-06-07 10:10
6765
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting
SHANGHAI, June 7, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated toZhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001,...
2021-06-07 10:00
4808
Hyperice Named Official Recovery Technology Partner by League of Legends Pro League
SHANGHAI, June 7, 2021 /PRNewswire/ -- League of Legends Pro League (LPL) and Hyperice, the industry leader in recovery technology and pioneer of percussion, vibration, dynamic air compression and thermal technology, today announced a partnership that names Hyperice the league's Official Recovery...
2021-06-07 10:00
4135
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021
* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...
2021-06-07 09:53
6840
CSOP Asset Management Ltd. Chooses SS&C to Support Operations
WINDSOR, Conn., June 7, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced thatHong Kong's CSOP Asset Management Ltd. has selected Eze Investment Suite for order management and portfolio accounting. Eze Investment Suite provides the flexibility CSOP required for ...
2021-06-07 09:00
11370
WeBank and SMU Nurture Future-Ready Fintech Talent with Blockchain Courses
SHENZHEN, China, June 7, 2021 /PRNewswire/ -- WeBank, the world's leading digital bank and the first digital-only bank inChina, announced that its summer enrichment programme onFISCO BCOS[1] Blockchain Experience at the Singapore Management University (SMU), a premier university in Asia internati...
2021-06-07 09:00
4398
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...
2021-06-07 08:30
4218
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8903
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
9034
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8858
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8800
Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries
ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...
2021-06-07 08:00
2941
Wood Mackenzie announces inaugural Power & Renewables APAC Conference
Industry leaders to discuss climate change policies and net-zero impact on APAC markets First public presentation of Wood Mackenzie Lens® Power SINGAPORE, June 7, 2021 /PRNewswire/ -- Wood Mackenzie invites registration for its inaugural Power & Renewables Asia Pacific (APAC) Conference onJune 2...
2021-06-07 07:00
4976
Primavera Capital Acquires Greater China Business of Mead Johnson from Reckitt Benckiser Group
BEIJING, June 6, 2021 /PRNewswire/ -- Primavera Capital Group ("Primavera") today announces that it has signed a definitive agreement with Reckitt Benckiser Group plc ("Reckitt"), a world's leading consumer health, nutrition, and hygiene company, to acquire theGreater China business of the Mead J...
2021-06-06 12:00
6032
Ucommune International Ltd. Announces Unaudited First Quarter 2021 Financial Results
BEIJING, Jun. 5, 2021 /PRNewswire/ -- Ucommune International Ltd. (NASDAQ: UK) ("Ucommune" or the "Company"), a leading agile office space manager and provider inChina, today announced its unaudited financial results for the first quarter endedMarch 31, 2021. First Quarter 2021 Financial Highli...
2021-06-05 04:30
16950
Mercurity Fintech Holding Inc. Reports First Quarter 2021 Financial Results
BEIJING, June 4, 2021 /PRNewswire/ -- Mercurity Fintech Holding Inc. (the "Company" or "MFH") (Nasdaq: MFH) today announced its unaudited financial results for the first quarter endedMarch 31, 2021. First Quarter 2021 Financial and Operating Highlights * Q1 2021 GAAP revenues of $81 thousand, ...
2021-06-05 04:05
16068
Remote village transforms into tourism hotspot
NUJIANG LISU AUTONOMOUS PREFECTURE, China, June 4, 2021 /PRNewswire/ -- This is a report from China SCIO about how a remote village inChina's southwestern Yunnan province transforms into a tourism hotspot: &amp;nbsp; During the early 2000s, life in Laomudeng was difficult. There was no ...
2021-06-04 21:00
3471
Huawei Achieves the World's Most Rigorous Energy Storage Standards Certified by TUV Rheinland
SHANGHAI, June 4, 2021 /PRNewswire/ -- At SNEC 2021, Huawei's smart string energy storage system (ESS) for residential use, the LUNA2000, received 2PfG 2511 and VDE-AR-E 2510-50 certificates from TUV Rheinland, aGermany-based testing and certification service provider. Li Weichun, Global Head of ...
2021-06-04 20:55
6325
Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia
SUZHOU, China, June 4, 2021 /PRNewswire/ -- Advaccine Biopharmaceuticals ("Advaccine") announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a respiratory syncytial virus (RSV) prophylactic vaccine candidate, inAustralia. The phase 2 study is a two-ce...
2021-06-04 20:05
4397
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 287 media titles]
2026-05-27 09:16
Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
6434
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
5489
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
5390
